Merck Expects Expedited Filing Of HDL-Cholesterol Drugs Using Existing Data

Merck believes it will be able to submit its developmental atherosclerosis therapies targeting HDL cholesterol without conducting major outcomes trials, Merck Research Lab President Peter Kim said during the firm's annual business review in Whitehouse Station, N.J. Dec. 15